Brain tumor drug trial fizzles: only 3 patients enrolled

NCT ID NCT05029960

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested whether brivaracetam, a seizure medication, is safe for people with diffuse gliomas (a type of brain tumor). Only 3 participants were enrolled before the study was terminated. The main goal was to track side effects, not to measure tumor shrinkage or survival. Because it ended early, no strong conclusions can be drawn.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Brivaracetam (a seizure drug)

What this could lead to

If it works, this could point toward a way to manage brain tumor symptoms safely.

What could go wrong

This was a very early, tiny trial (only 3 people) that ended early. It cannot prove effectiveness, and the drug may cause side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRAIN TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain cancer brain neoplasm epilepsy glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Rochester Medical Center

    Rochester, New York, 14642, United States